Ironwood Pharmaceuticals, Inc. — Earnings Quality Grade F
IRWD · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 58 days, change -27 days YoY
AR growth -42.9% vs revenue growth -15.7%
Revenue -15.7%, CFFO 22.7%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -76.1% vs revenue -15.7%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 5.29. Profits backed by cash
FCF $0.1B, FCF/NI = 5.29
Accruals ratio = -26.0%. Low accruals
Cash $0.2B covers only 36% of debt $0.6B
Balance Sheet Health
Goodwill+Intangibles $0.0B = -1% of equity. Manageable
Debt/EBITDA = 5.7x (>4x). Financial stress
Other assets -24.0% vs revenue -15.7%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -29% YoY. Normal
Manipulation Score
Insufficient data
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25